Zevra Therapeutics (ZVRA) Long-Term Debt Repayments (2016 - 2024)
Historic Long-Term Debt Repayments for Zevra Therapeutics (ZVRA) over the last 7 years, with Q2 2024 value amounting to $42.7 million.
- Zevra Therapeutics' Long-Term Debt Repayments rose 2052801.93% to $42.7 million in Q2 2024 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year decrease of 997.45%. This contributed to the annual value of $42.7 million for FY2024, which is 14356.85% up from last year.
- Zevra Therapeutics' Long-Term Debt Repayments amounted to $42.7 million in Q2 2024, which was up 2052801.93% from $4.7 million recorded in Q4 2023.
- Zevra Therapeutics' Long-Term Debt Repayments' 5-year high stood at $42.7 million during Q2 2024, with a 5-year trough of -$207000.0 in Q3 2023.
- In the last 3 years, Zevra Therapeutics' Long-Term Debt Repayments had a median value of $8.8 million in 2023 and averaged $16.4 million.
- Examining YoY changes over the last 5 years, Zevra Therapeutics' Long-Term Debt Repayments showed a top increase of 2052801.93% in 2024 and a maximum decrease of 2052801.93% in 2024.
- Zevra Therapeutics' Long-Term Debt Repayments (Quarter) stood at $37.9 million in 2021, then plummeted by 87.53% to $4.7 million in 2023, then skyrocketed by 802.56% to $42.7 million in 2024.
- Its Long-Term Debt Repayments stands at $42.7 million for Q2 2024, versus $4.7 million for Q4 2023 and -$207000.0 for Q3 2023.